Top of page

Executive Compensation

Practice

Filters

Royalty Pharma $2.5 billion IPO

Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $2.5 billion initial public offering…

ADC Therapeutics $267 million IPO

Davis Polk advised ADC Therapeutics SA on its SEC-registered initial public offering of 14,082,475 common shares, which…
Back to top